Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Dec 04 2020

· Issued by Zydus Lifesciences Limited

Filed with NSE ·

Cadila Healthcare Limited has informed the Exchange regarding a press release dated December 04, 2020, titled "Zydus receives approval from DCGI to commence Phase III clinical trials with Pegylated Interferon alpha-2b in India".

View Attachment

6ix hasn’t read this filing yet.

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases